Consonance Capital

Consonance Capital Partners, LP is a private equity firm based in New York, specializing in investments within the healthcare sector. Founded in 2005, the firm focuses on lower middle-market companies, particularly in areas such as healthcare providers, payors, pharmaceuticals, medical devices, and healthcare technology. Consonance Capital engages in various investment strategies, including growth capital, leveraged buyouts, and recapitalizations, typically investing between $20 million and $45 million per transaction in companies with revenues ranging from $25 million to $500 million. The firm also manages public equity investments through its affiliate, Consonance Capital Management, employing a long/short strategy. Through its diverse investment approach, Consonance Capital aims to enhance healthcare efficiency and innovation while managing client-focused equity portfolios.

Mitchell Blutt

Managing Partner and Co-Founder

Sean Breen

Partner & Founding Member

Nancy-Ann DeParle

Co-Founder & Managing Partner

Benjamin Edmands

Co-Founder & Managing Partner

Alex Flick

Senior Associate

Katherine Guan

Associate

Sapna Tejwani Jethwa

Vice President

Michael Lituchy

Associate

Stephen McKenna

Co-Founder & Managing Partner

Mary Sobon

CFO

Javier Starkand

Partner & Founding Member

Peter Weinberg

Vice President

Michael Zhuang

Vice President

10 past transactions

Civic Eagle

Series A in 2022
Civic Eagle develops software that helps companies discover and analyze legislation and regulations with no manual work. Civic Eagle's platform searches, tracks, and works with legislations across the country and does the discovery work so that policy advocates can focus on winning campaigns, thereby enabling clients to promote better democratic outcomes for people and their communities. It was founded in 2015 and headquartered in Minneapolis, Minnesota.

Surrozen

Post in 2021
Surrozen, Inc. is a biopharmaceutical company based in South San Francisco, California, that specializes in developing targeted regenerative antibodies aimed at repairing tissues and organs affected by serious diseases. The company utilizes antibody platforms that act as Wnt and R-spondin mimetics to stimulate cell and organ-specific tissue regeneration. Its key programs include SZN-043, which is designed to promote hepatocyte regeneration in both acute and chronic liver diseases, and SZN-1326, an intestine-specific Wnt-mimetic intended to repair diseased epithelial tissue for patients suffering from inflammatory bowel disease. Surrozen was incorporated in 2015 and is focused on harnessing the body's self-renewal capabilities through precise control of the Wnt signaling pathway.
Silence Therapeutics is a biotechnology company based in the United Kingdom that specializes in the discovery and development of innovative RNA therapeutics for various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. The company utilizes short interfering RNA (siRNA) technology to target and degrade specific messenger RNAs, thereby modulating gene expression. Its notable product candidates include SLN124, aimed at treating iron overload disorders by silencing the TMPRSS6 gene, and SLN360, which targets the LPA gene to lower lipoprotein levels and reduce cardiovascular risks. Silence Therapeutics also engages in strategic collaborations, including a partnership with AstraZeneca to advance small interfering RNA therapeutics for multiple disease areas. Established as SR Pharma plc, the company rebranded to Silence Therapeutics in 2007 and is headquartered in London.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. It was founded in 2005 and headquartered in Cambridge, Massachusetts.

Orsini Healthcare

Acquisition in 2019
Orsini Healthcare is a boutique, nationwide specialty pharmacy that focuses on programs for rare and complex medical conditions.

Psychiatric Medical Care

Acquisition in 2018
Psychiatric Medical Care is a mental health care company specializing in stress management services.

Bako Diagnostics

Acquisition in 2016
Bako Integrated Physician Solutions is the premier provider of diagnostic and therapeutic services focusing on the skin, soft tissue and bone of the lower extremity. Their pathology team provides not just information, but also intelligence to enable better patient care.

Telesta Therapeutics

Venture Round in 2015
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.

Enclara Pharmacia

Acquisition in 2014
Enclara Pharmacia, Inc. is a comprehensive mail order and pharmacy benefit management (PBM) supplier specializing in medications and clinical services for the hospice and palliative care sectors. The company provides a range of solutions, including hospice mail order pharmacy services, clinical support, business intelligence tools, and educational resources tailored to meet regulatory requirements and enhance medication dispensing systems. Enclara serves hospice providers and patients across the United States, aiming to improve patient experience and quality of care while managing costs. Founded in 1996 and based in Philadelphia, Pennsylvania, Enclara Pharmacia operates as a subsidiary of Eagle RX, Inc., following its rebranding from excelleRx, Inc. in 2014. The company focuses on streamlining care delivery through collaboration with healthcare organizations, leveraging technology and best practices to optimize operational efficiencies in hospice care.

Kepro

Acquisition in 2014
Since 1985, KEPRO has helped 20 million members lead healthier lives through clinical expertise, integrity and compassion. Our values are promises we keep every day. And why we keep growing with our clients.